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| INTRODUCTION
Acute coronary syndrome (ACS) is provoked by disruption (rupture or erosion) of coronary atherosclerotic plaques and subsequent thrombus formation. 1 Thrombi produced on disrupted plaques comprise aggregated platelets and considerable amount of fibrin; therefore, a tissue factor-mediated coagulation pathway plays a critical role in thrombus formation that leads to the onset of ACS. [2] [3] [4] Tissue factor (TF) expression by macrophages and smooth muscle cells in plaques 5, 6 is induced by proinflammatory cytokines such as interferon-γ (IFNγ), tumor necrosis factor-alpha (TNFα), lipopolysaccharide, as well as hypoxia, [5] [6] [7] and its procoagulant activity is inhibited by TF pathway inhibitor (TFPI). 8 Tryptophan (Trp) is an essential amino acid that is either used for protein synthesis or metabolized to various bioactive molecules via the serotonin pathway or the kynurenine (Kyn) pathway, and the latter pathway is the major route of Trp catabolism in humans. 9 Catabolites in the Kyn pathway of Trp catabolism are important for regulating the immune system and inflammation. 10, 11 Emerging evidence also indicates that these catabolites play significant roles in cardiovascular pathophysiology. [12] [13] [14] Indoleamine 2, 3-dioxygenase (IDO) is an enzyme that catalyzes the first and rate-limiting step of Trp metabolism along the Kyn pathway 9 and it has two isoforms. The IDO1 isoform is expressed in various tissues, including dendritic cells, endothelial cells, macrophages, fibroblasts, and mesenchymal stromal cells, and this major isoform contributes to Trp degradation. The IDO2 isoform is primarily expressed in the kidney, brain, colon, liver, and reproductive tract. 9, 14 The expression of IDO2 is apparently basal, whereas that of IDO1 is induced by cytokines, particularly IFNγ. 15 IDO1 is overexpressed in many pathological states such as cancer, autoimmune, cardiovascular, and inflammatory bowel diseases. 16 IDO1 is thought to cause immune escape via local Trp degradation and subsequent inhibition of the T cell response. 17 According to the inflammatory nature of atherosclerotic diseases, the serum Kyn/Trp ratio increases in patients with coronary heart diseases, 18 and plasma or urinary Kyn/Trp ratios or plasma Kyn values are associated with coronary thrombosis and cardiovascular mortality. [19] [20] [21] Plasma levels of TF, Kyn, and Kyn/Trp ratios are significantly increased, whereas TFPI remains unchanged in in patients with chronic kidney disease (CKD). 22 These lines of evidence suggest that IDO1 and the Kyn pathway significantly contribute to cardiovascular diseases and thrombus formation. However, IDO1 expression in human coronary arteries and its role(s) in vascular wall thrombogenicity remains unknown.
We therefore evaluated the expression of IDO1 in human coronary atherosclerotic plaques and its contribution to TF expression in macrophages activated using cytokines. 
| MATERIAL S AND ME THODS

| Cell culture
The human monocyte THP-1 cell line (Dainippon Sumitomo Pharma, Suita, Japan) was maintained in a subconfluent state (5 × 10 5 cells/ mL) in RPMI-1640 medium supplemented with 10% fetal bovine
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serum and 1% Zell Shield (Minerva Biolabs, Berlin, Germany) at 37°C in a humidified incubator. 
| Trp and Kyn concentrations in cell culture supernatants measured using liquid chromatography/ mass spectrometry
Frozen supernatants from THP-1 cell cultures were thawed, maintained at 4°C, deproteinized using the same volume of 6% trichloroacetic acid and kept on ice for 30 minutes. The samples were separated by centrifugation at 5800 g for 15 minutes at 4°C.
Levels of Trp and Kyn in the supernatants were measured using liquid chromatography/mass spectrometry (LC-MS) with some modification. 23 A Zorbax stable-bond C8 reversed-phase analytical column measuring 150 × 4.6 mm with a particle size of 3.5 μm (Agilent Technologies, Tokyo, Japan) was mounted in a compartment with a thermostat set at 40°C. The mobile phase comprised 95% solution A (650 mmol/L acetic acid) and 5% solution B (acetonitrile). Calibration curves were prepared using L-tryptophan reference material (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and l-kynurenine (K6825; Sigma-Aldrich). Samples (10 μL)
were injected into the column and detected using Q Exactive (Life Technologies, Carlsbad, CA, USA).
| Measurement of mRNA expression using real time PCR
Activated THP-1 macrophages in six-well plates were washed with PBS (2 mL) three times and resolved with 1 mL TRIzol (Life Technologies). Total RNA was extracted using RNeasy Mini Kits (Qiagen, Hilden, Germany) and quantified using a Nano Drop 1000
(ND-1000) spectrophotometer (Thermo Scientific, Rockford, IL, USA). Single-strand, complementary DNA (cDNA) was synthesized from the RNA using PrimeScript RT reagent kits (Perfect Real Time, Takara Bio, Shiga, Japan) and used for real time PCR. Gene expression was measured using a LightCycler 480 (Roche Diagnostics GmbH, Mannheim, Germany), SYBR Premix EX Taq II (Perfect Real Time, Takara Bio) and specific primers with the following sequences:
human TF, 5′-TGACCTCACCGACGAGATTGTGAA-3′ (forward) and 5′-TCTGAATTGTTGGCTGTCCGAGGT-3′ (reverse); human TFPI, 5′-TGGATGCCTGGGCAATATGA-3′ (forward) and 5′-AGGCTGGGAA CCTTGGTTGA-3′ (reverse); human β-actin, 5′-TGGCACCCAGCACAA TGAA-3′ (forward) and 5′-TAAGTCATAGTCCGCCTAGAAGCA-3′.
Gene expression was normalized by β-actin expression.
| Enzyme-linked immunosorbent assay (ELISA)
Cellular or nuclear and cytoplasmic proteins were extracted using RIPA buffer (Nacalai Tesque, Kyoto, Japan) or NE-PER Nuclear and Cytoplasmic Extraction Reagents (Life Technologies) containing 1%
Halt protease and phosphatase inhibitor (Life Technologies). Protein concentrations were determined using Pierce BCA Protein Assay Kits (Life Technologies). Amounts of TF and TFPI expression and NFκB (p65) activity in THP-1 macrophages were measured using Q uantikine ELISA kits for human TF and TFPI (R&D Systems), and NFκB (p65)
Transcription Factor Assay Kits (ab133112; Abcam), respectively.
| Factor Xa chromogenic activity of tissue factor measurement
Factor Xa chromogenic activity of THP-1 macrophages was assessed using Tissue Factor Human Chromogenic Activity Assay Kits (ab108906; Abcam). Activated THP-1 macrophages in six-well plates were washed with cold PBS (2 mL) three times, then 300 μL of octyl-β-d-glucopyranoside containing 1% Halt protease inhibitor (Life Technologies) was added and the mixtures were placed at 37°C for 15 minutes. The lysates were collected into 1.5-mL microtubes and stored at −80°C. Chromogenic activity was assayed according to the manufacturer's instructions.
| Western blotting
The expression of AHR in the nuclei and the cytoplasm of THP-1 macrophages was assessed as follows. The cells were resolved using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Life 
| Statistical analysis
Data were analyzed using JMP 11. Values with P < 0.05 were considered to be statistically significant. Table 1 shows the clinical characteristics of the patients with SAP (n = 20) and UAP (n = 20) from whom we obtained DCA samples.
| RESULTS
| Characteristics of patients with SAP and UAP
Only diabetes was significantly more prevalent in patients with UAP than SAP (P < 0.05). Medications did not significantly differ between the groups.
| Tissue factor and IDO1 in human coronary plaque
We immunohistochemically examined the expression and localization of IDO1 and TF in serial sections of human DCA samples. Figure 1D and E). 
| Induction of IDO1 and expression of TF in THP-1 macrophages activated using IFNγ and TNFα
Since both IDO1 and TF were detected in macrophage-rich coronary plaques, we examined IDO1, TF, and TFPI expression in macrophages derived from THP-1. Macrophages derived from inactivated THP-1 expressed low levels of IDO1 mRNA, whereas IDO1 mRNA expression at 12 hours was increased 400-fold in macrophages from THP-1 cells activated with IFNγ and TNFα ( Figure   S1A ). The expression of TF mRNA and protein in the activated macrophages was significantly increased for up to 24 hours ( Figure S1B and D). In contrast, TFPI mRNA and protein expression decreased over time in both inactivated and activated macrophages, and the amount of mRNA was significantly reduced at 3, 6, and 12 hours in activated macrophages ( Figure S1C and E). The ratio of TF to TFPI protein was higher in activated, than in inactivated macrophages at 24 hours ( Figure S1F ).
| IDO1 catalyzes Trp into Kyn, and enhances TF expression in activated macrophages
We measured Trp and Kyn concentrations in cell culture supernatants using LC-MS to determine IDO1 enzymatic activity in activated macrophages. Levels of Trp and Kyn in the supernatant were 
| Kynurenine partly contributes to cytokineinduced TF expression via the Kyn receptor, AHR
We evaluated TF expression in activated macrophages when endogenous Kyn production was inhibited by epacadostat to determine whether or not the Kyn pathway metabolites kynurenine, 3-hydroxyanthranilic acid, and quinolinic acid contribute to TF expression in macrophages activated with IFNγ and TNFα. Kynurenine dose-dependently increased TF mRNA expression under IDO1 inhibition whereas hydroxyanthranilic and quinolinic acids did not. The range of kynureine concentrations (10-200 μg/mL) was selected based on a previous study. 24 However, TF expression did not reach the level of the inflammatory activated control ( Figure 3A , Figure   S7 ).
We investigated the nuclear translocation and contribution of 
| DISCUSSION
The present study found that IDO1 and TF were closely localized in human coronary atherosclerotic plaque, that IDO1 and TF were predominant in plaques from patients with UAP, and that IDO1 and Kyn contributed to TF expression in macrophages activated with IFNγ and TNFα.
Macrophages in human coronary plaques contained IDO1. The
Tampere Vascular Study found that IDO1 expression is elevated in the macrophage-rich cores of advanced atherosclerotic lesions. 25 Levels of Kyn that reflect IDO1 activity are increased in human unstable plaques 26 and in rabbit macrophage-rich atherosclerotic arteries. 27 In addition, IDO1 activity in blood significantly and positively correlates with more advanced degrees of atherosclerosis. 
from samples of coronary plaque, and this was more obvious in patients with UAP than SAP. These and previous findings are comparable. However, not all macrophages were positive for IDO1, which might have been due to heterogeneity among macrophages and inflammatory stimuli in human plaques. Although we did not assess cytokine levels, several inflammatory cytokines including IFNγ and TNFα are increased in blood and atherosclerotic plaques from patients with ACS.
29,30
The expression of IDO1 positively correlated with TF expression in plaque. The overexpression of TF in atherosclerotic lesions contributes to platelet-fibrin thrombus formation via excess thrombin generation during plaque disruption. 2, 31 We previously correlated TF expression with coronary thrombus size, which is a determinant of the onset of ACS. 4 Macrophages and smooth muscle cells in plaques express TF, and this is induced by many stimuli, including inflammatory cytokines, hypoxia, oxidized low-density lipoprotein, and Creactive protein. 6, 32 We localized TF and IDO1 in macrophages from Kyn/Trp ratios predict increased risk of acute myocardial infarction in patients with stable angina pectoris. 21 Pawlak et al significantly associated TF, TFPI, and prothrombin fragments 1 + 2 with levels of Kyn pathway metabolites in patients with uremia on dialysis. 33 Such evidence suggests that plasma Kyn values or Kyn/Trp ratios could be markers with which to predict cardiovascular events.
Gene expression of TF is regulated by transcriptional factors such as NFκB, SP-1 and AP-1 34, 35 and/or mRNA stabilization and NFκB is a major transcriptional factor for inducible TF expression.
We found that inhibiting IDO1 activity using epacadostat reduced NFκB (p65) binding activity in the nuclei of THP-1 macrophages activated using IFNγ and TNFα. Although the precise mechanism(s) remains unknown, the present findings suggest that transcriptional upregulation via NFκB rather than mRNA stability contributes to IDO1 mediated TF upregulation. Tryptophan and kynurenine concentrations in supernatants were measured using LC-MS at indicated times. Inflammatory stimuli reduced levels of tryptophan and increased those of kynurenine in the supernatants, whereas epacadostat reduced kynurenine production under inflammatory stimuli. *P < 0.001, † P < 0.0001 (two-way ANOVA followed by Bonferroni correction). Effects of epacadostat on expression of TF mRNA, protein and chromogenic activity in activated THP-1 macrophages at 3 (mRNA) or 24 (protein and chromogenic activity) hours (n = 5 each; C-E). Effects of Epacadostat on NFκB (p65) binding activity in activated THP-1 macrophages at 2 hours (n = 6 each [F]). *P < 0.05, † P < 0.01, ‡ P < 0.001, § P < 0.0001, one-way ANOVA followed by Bonferroni correction. LC-MS, liquid chromatography-mass spectrometry; ns, not significant; TF, tissue factor TF protein TF activity TF mRNA NFKB (p65) binding activity
The ligand-inducible transcription factor AHR, which mediates the toxic effects of dioxins and uremic toxins, has recently emerged as a pathophysiological regulator of immune-inflammatory conditions and Kyn is an endogenous ligand for AHR. 36 Activating AHR promotes both atherosclerosis in mice with an apolipoprotein E deficiency, 37 and leukocyte endothelial interaction induced by TNF-α.
38
The findings of clinical studies have suggested that AHR contributes to thrombotic complications in patients with chronic kidney disease. 39, 40 Indolic uremic sulfates, levels of which are increased in patients with chronic kidney disease, enhance TF mRNA and protein expression in endothelial and peripheral blood mononuclear cells via the AHR pathway. 39 The AHR receptor regulates TF protein stability via TF ubiquitination and degradation. 40 The present findings showed that Kyn enhances TF expression via AHR under IDO1 inhibition in activated macrophages. However, the contribution of the Kyn-AHR pathway to TF expression in macrophages is only partial, 42 The present findings showed that epacadostat not only reduced IDO1 activity, but also suppressed TF expression via NFκB (p65) binding activity and Kyn production. This suggests that epacadostat could help to prevent coronary thrombosis. However, further studies are required, because whether or not IDO1 can prevent atherosclerosis remains controversial. 26, 43, 44 This study has several limitations. Serum levels of the inflammatory cytokines, Trp, and Kyn were not investigated due to the retrospective design. Therefore, we could not show a relationship between serum parameters and IDO1 expression in coronary atherosclerotic plaques. Because coronary atherectomy samples were obtained from parts of atherosclerotic plaques, the data might not represent entire atherosclerotic lesions derived from patients.
We mainly used a human leukemic monocyte THP-1 cell line.
Nonetheless, similar to peripheral blood monocytes, IDO1 and TF were expressed after stimulation with cytokines, and the IDO1 inhibitor, epacadostat, reduced TF expression in macrophages derived from this line.
We did not investigate the contribution of IDO1 to TF expression in atherosclerotic plaque and thrombus formation in vivo. Further study is required to determine role of IDO1 on atherothrombosis in vivo.
In conclusion, enhanced IDO1 expression in coronary atherosclerotic plaque might contribute to atherothrombosis through TF upregulation in activated macrophages.
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